(Reuters) - Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.O) experimental vaccine meant to prevent infection with the Ebola virus.
Large late-stage trials of the product could begin early next year, Merck said.
Read more